Nutrition Impact on Immunotherapy of Cancer

Launched by QINGDAO CENTRAL HOSPITAL · Jul 12, 2024

Keywords

ClinConnect Summary

This clinical trial, titled "Nutrition Impact on Immunotherapy of Cancer," is exploring how a patient’s nutritional status may affect the outcomes of cancer treatments known as immunotherapy. Immunotherapy helps the body’s immune system fight cancer, and this study aims to see if being well-nourished can improve the effectiveness of these treatments. The trial is currently recruiting participants aged 18 and older who have been diagnosed with cancer and are experiencing malnutrition. Participants should have a measurable cancer lesion and normal organ function, and they must be able to swallow oral medications comfortably.

If you or a family member meet these eligibility criteria, you may be able to participate in this important research. Participants can expect to be monitored closely throughout the study, and they will need to follow specific guidelines to ensure their health and safety. It's also important to note that individuals with certain medical conditions or those taking specific medications may not be eligible for this trial. This study could provide valuable information about the role of nutrition in cancer treatment, potentially leading to better outcomes for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of cancer, malnutrition Age \>18 years Performance status ECOG of 0 or 2. Life expectancy ≥ 6 months. At least one lesion measurable as defined by standard imaging criteria for the patient's tumor type (RECIST v1.1) Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment Postmenopausal or evidence of non-childbearing status for women of childbearing potential Patient is willing and able to comply with the protocol for the duration of the study.
• • For all oral medications patients must be able to comfortably swallow capsules;
• Exclusion Criteria:
• • Patients unable to swallow orally administered medication and patients with Impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption of oral drugs History of allogenic organ, bone marrow or double umbilical cord blood transplantation.
• • Active or prior documented autoimmune or inflammatory disorders Uncontrolled intercurrent illness or patient considered a poor medical risk due to a serious, uncontrolled medical disorder, including but not limited to, ongoing or active infection, symptomatic congestive heart failure Currently taking medications with known risk of prolonging the QT interval or inducing Torsades de Pointes.